AP‐HP

:   Assistance Publique‐Hôpitaux de Paris

COVID‐19

:   2019 novel coronavirus disease

RT‐PCR

:   reverse‐transcription‐polymerase chain reaction

SARS‐Cov‐2

:   severe acute respiratory syndrome coronavirus 2

Dear editor,

 {#ijc33167-sec-0001}

Some publications have reported highest risk of severe complications of 2019 novel coronavirus disease (COVID‐19) in cancer patients.[^1^](#ijc33167-bib-0001){ref-type="ref"} To date, quarantine is the only recommended preventive attitude against COVID‐19. Cancer patients that still need hospital care deserve early diagnosis of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) infection to adapt treatment strategies and halt nosocomial transmission. High proportion of asymptomatic patients, the absence of validated serological testing and the limitations of systematic mass testing by reverse transcription‐polymerase chain reaction (RT‐PCR), hamper the control of COVID‐19 outbreak.[^2^](#ijc33167-bib-0002){ref-type="ref"} Reported rates of 40% of hospital‐related transmission of SARS‐Cov‐2 argue that our current preventive approaches testing are inadequate.[^3^](#ijc33167-bib-0003){ref-type="ref"} Therefore, oncologists should adopt alternative device in cancer patients. We report a strategy of systematic detection of COVID‐19 symptoms with patient‐reported questionnaire in cancer patients.

We prospectively used a systematic questionnaire covering symptoms of COVID‐19 in patients admitted at the Department of Oncology at Tenon Hospital (AP‐HP Sorbonne Université) as outpatient or inpatient from March 9 to April 3, 2020 (data cutoff date). All patients underwent temperature measurement at admission. Patients with at least one relevant symptom were appraised by oncologist and underwent nasal swab for SARS‐Cov‐2 detection by RT‐PCR. Clinical data of patients were retrieved from computer files. Patients with thoracic and hematological malignancies were excluded as managed by other departments.

We admitted 987 patients in our department and 610 (61.8%) were screened by questionnaire. Sixty‐two (10.2%) were hospitalized. Clinical characteristics of patients are summarized in Table [1](#ijc33167-tbl-0001){ref-type="table"}. The median age was 61.5 years, and 462 patients (75.7%) were female; 315 (51.6%) had breast cancer, and 346 (56.7%) were metastatic. Most of patients (n = 480, 78.7%) were being treated with cancer treatment within the 30 previous days, mainly chemotherapy (n = 238, 39.0%). Only 160 patients (26.2%) reported at least one symptom, from which 38 (23.8%) underwent nasal swab. Nine patients (1.5%) were PCR‐positive, from which four (44.4%) were hospitalized. The median age was 53.8 years. Seven patients (77.8%) were female; three (33.3%) had breast cancer and three (33.3%) ovarian cancer. Six patients (66.7%) were metastatic. Most of patients (n = 8, 88.9%) were receiving cancer treatment, mostly chemotherapy (n = 5, 55.6%). Three patients (33.3%) required low‐flow oxygen therapy, two (22.2%) received antibiotics and none required intensive‐level care. Median hospitalization duration after SARS‐Cov‐2 infection suspicion was 27 days. As of April 24, 2020, eight patients (88.9%) were discharged and one patient (11.1%) died from cancer progression.

###### 

Clinical characteristics of cancer patients screened by patient‐reported outcomes questionnaire in the Department of Radiotherapy and Medical Oncology

                                                              All population                                        Patients infected with SARS‐Cov‐2
  ----------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------
  Median age (years, range)                                   61.5 (19.5‐94.1)                                      53.8 (30.9‐86.1)
  \> 60                                                       335 (54.9)                                            3 (33.3)
  Gender                                                                                                            
  Female                                                      462 (75.7)                                            7 (77.8)
  Comorbidities                                                                                                     
  Hypertension                                                186 (30.5)                                            1 (11.1)
  Diabetes                                                    76 (12.5)                                             1 (11.1)
  Chronic Kidney Disease                                      20 (3.3)                                              1 (11.1)
  Obesity[^a^](#ijc33167-note-0002){ref-type="fn"}            90 (14.8)                                             0 (0)
  None                                                        339 (55.6)                                            5 (55.6%)
  Smoking status                                                                                                    
  Current smoker                                              115 (18.9)                                            1 (11.1)
  Former or never smoker                                      495 (81.1)                                            8 (88.9)
  Primitive cancer location                                                                                         
  Breast                                                      315 (51.6)                                            3 (33.3)
  Ovarian                                                     54 (8.9)                                              3 (33.3)
  Prostate                                                    50 (8.2)                                              0 (0)
  Colorectal                                                  32 (5.2)                                              0 (0)
  Head and neck                                               31 (5.1)                                              0 (0)
  Other                                                       128 (21.0)[^b^](#ijc33167-note-0003){ref-type="fn"}   3 (33.3)[^c^](#ijc33167-note-0004){ref-type="fn"}
  Tumor stage                                                                                                       
  Non metastatic                                              246 (40.3)                                            3 (33.3)
  Metastatic                                                  346 (56.7)                                            6 (66.7)
  Cancer treatment[^d^](#ijc33167-note-0005){ref-type="fn"}   480 (78.7)                                            8 (88.9)
  Chemotherapy                                                238 (39.0)                                            6 (55.6)
  ICI                                                         28 (4.6)                                              0 (0)
  Endocrine therapy                                           123 (20.2)                                            1 (11.1)
  Molecular targeted therapy                                  148 (24.3)                                            2 (22.2)
  Radiotherapy                                                83 (13.6)                                             1 (11.1)
  Follow‐up                                                   58 (9.5)                                              0 (0)
  Exclusive palliative care                                   15 (2.5)                                              0 (0)
  COVID‐19 symptoms                                           160 (26.2)                                            9 (100)
  Fever \>38°C                                                24 (3.9)                                              6 (66.7)
  Shortness of breath                                         32 (5.2)                                              3 (33.3)
  Cough                                                       51 (8.4)                                              7 (77.8)
  Rhinitis                                                    78 (12.8)                                             1 (11.1)
  Sneeze                                                      35 (5.7)                                              1 (11.1)
  Ocular discomfort                                           24 (3.9)                                              0 (0)
  Myalgia                                                     19 (3.1)                                              1 (11.1)
  Anosmia                                                     7 (1.1)                                               2 (22.2)
  Agueusia                                                    6 (1.0)                                               2 (22.2)
  Contact with confirmed COVID‐19 case                        15 (2.5)                                              5 (55.6)
  RT‐PCR COVID‐19 testing                                     38 (6.2)                                              9 (100)
  Positive                                                    9 (1.5)                                               9 (100)
  Negative                                                    29 (4.8)                                              0 (0)

Abbreviations: ICI, immune checkpoint inhibitor; SARS‐Cov‐2, severe acute respiratory syndrome coronavirus.

Obesity is defined as body mass index over 30 kg/m^2^.

Twenty‐three patients (3.8%) had bladder cancer, 20 (3.3%) endometrial cancer, 15 (2.5%) sarcoma tumor, 14 (2.3%) pancreatic cancer, 12 (2.0%) renal cancer, nine trophoblastic tumor, eight cervical cancer, seven testicular cancer, five esophageal cancer, four gastric cancer, three anal cancer, two carcinoma from unknown primitive, two peritoneal cancer, one hepatocarcinoma and one small intestine cancer.

One patient had pancreatic cancer, one bladder cancer and one cervical cancer.

Includes treatments received within the 30 previous days.

We estimated the incidence rate of COVID‐19 among cancer patients at 1.5%, consistently with previous results.[^1^](#ijc33167-bib-0001){ref-type="ref"} This might be underestimated due to asymptomatic forms of COVID‐19, low specificity of COVID‐19 symptoms in context of malignancies and false‐negative results of RT‐PCR assay. In the event of a chronic pandemic, serological tests might then prove essential to halt viral spread, if validated in cancer patient population. Also, cancer outpatients might be better self‐protected due to usual caution given to barrier preventive measures. One of limitation in our study is the lack of screening of digestive symptoms, potentially compatible with COVID‐19. Most of screened patients were not male (75.7%) and had no comorbidity (55.6%), factors predisposing to COVID‐19 and severe forms.[^4^](#ijc33167-bib-0004){ref-type="ref"} Finally, we excluded patients with thoracic and hematological malignancies, also at risk of COVID‐19 and severe events.[^1^](#ijc33167-bib-0001){ref-type="ref"} Nine patients were diagnosed with COVID‐19 and none developed severe form, contrary to other studies including mostly cancer survivors or lung cancer patients.[^5^](#ijc33167-bib-0005){ref-type="ref"}, [^6^](#ijc33167-bib-0006){ref-type="ref"} Given the absence of severe form of COVID‐19, we did not study biological prognostic factors, probably poorly specific in cancer patients.[^4^](#ijc33167-bib-0004){ref-type="ref"} Large‐scale data are needed to further explore risk factors of COVID‐19 severity in this population.
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